US housing activity weakened sharply in July, with single-family homebuilding hitting a more than three-and-a-half-year low as high mortgage rates and economic uncertainty weighed on demand. In contrast, factory output rose, supported by strong AI-related investment and demand for high-tech equipment and semiconductor production.
Persistently high US Treasury auction yields are raising the cost of refinancing government debt and funding future deficits as investors demand greater compensation to absorb rising borrowing needs. Recent 10-year and 30-year auctions saw yields hit multi-year highs, though resilient demand suggests there is no broad buyer strike. The key concern for Washington is the growing cost of servicing a large and persistent fiscal deficit.
Four Nifty500 stocks surged over 5% on August 18, triggering StockEdge’s White Marubozu bullish scanner, signalling strong buying momentum and sustained investor interest across these stocks.
The impressive earnings reported in the first quarter have led brokerages to unveil fresh stock-picking avenues. Investors are encouraged to seek out firms showcasing strong earnings and solid financial fundamentals. A collective effort from various brokerages has resulted in the identification of fifty prime stock options, covering diverse industries such as banking, automotive, and defense. The market is now pivoting towards an earnings-led cycle with an emphasis on quality companies.
Symbiotec Pharmalab will launch its ₹1,757-crore IPO from August 24–27, 2026, with a price band of ₹938–988 per share. The minimum bid is 15 shares, requiring an investment of ₹14,820 at the upper price band. The IPO is expected to list on BSE and NSE on September 1, with allotment likely on August 28. At the upper band, the issue values the company at a steep 52 times FY26 diluted EPS.
The three-day IPO will remain open until August 21, 2026, with the company offering shares in a price band of Rs 152–160 apiece.
Mazagon Dock Shipbuilders in April had announced that its board of directors have recommended a final dividend of Rs 4.62 per share for the financial year 2026. The company later fixed August 20 as the record date to determine the eligibility of shareholders set to receive the payment.
The IPO, which was open for subscription from August 12 to August 14, drew an overwhelming response from investors and was subscribed 108.44 times overall. The retail portion was subscribed 53.27 times, while the QIB and NII categories saw exceptionally strong demand, with subscriptions of 165.33 times and 165.32 times, respectively.
Mumbai-based Milky Mist Dairy Foods made a strong debut on the NSE, listing at ₹165—17.9% above its issue price of ₹140. The stock climbed further to close at the day’s high of ₹181.50, valuing the company at ₹13,972.66 crore at the close.
Warning! Information Posting in this website is only for educational purpose. We are not responsible for losses incurred in Trading based on this information.